FDA Accepts Praxis' Ulixacaltamide NDA for Essential Tremor, Sets January 2027 PDUFA Date
Summary
Praxis Precision Medicines announced that the FDA has accepted its New Drug Application (NDA) for ulixacaltamide HCl for the treatment of essential tremor, assigning a PDUFA target action date of January 29, 2027. This is a critical regulatory milestone, confirming the FDA will proceed with a full review of the drug, which previously received Breakthrough Therapy Designation and showed positive Phase 3 results. The absence of a planned advisory committee meeting is generally viewed as a positive indicator, suggesting a potentially smoother path to approval. This acceptance significantly de-risks a key pipeline asset for Praxis, providing a clear timeline for potential commercialization. Investors will now closely monitor the PDUFA date for the final regulatory decision.
At the time of this announcement, PRAX was trading at $350.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.8B. The 52-week trading range was $28.08 to $356.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.